Principal Scientist, Medicinal Chemistry job with Silverback Therapeutics acs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acs.org Daily Mail and Mail on Sunday newspapers.
Bright Peak Therapeutics Announces $107 Million Series B globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Proceeds to advance company's pipeline of next-generation cytokine immunotherapies Laura Shawver, Christine Siu join as independent directors BASEL, Switzerland and SAN DIEGO, Calif., June 10
Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
Markets
In a report issued on April 27, Daina Graybosch from Leerink Partners maintained a Buy rating on Affimed (AFMD – Research Report). The company’s shares closed last Wednesday at $11.40.
According to TipRanks.com, Graybosch is a 4-star analyst with an average return of 20.2% and a 47.5% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Molecular Partners AG, and Bolt Biotherapeutics.
Affimed has an analyst consensus of Strong Buy, with a price target consensus of $14.00, implying a 26.0% upside from current levels. In a report issued on April 12, BMO Capital also maintained a Buy rating on the stock with a $15.00 price target.